AstraZeneca Results Presentation Deck
tozorakimab
Severe viral lung infection
Airway epithelium
Airway endothelium
Staining showed localised IL-33 in airway
IL-33red/sST2 levels associated with
poor clinical outcomes
ST2 expressed in alveolar capillary cells
ATS
BioPharmaceuticals - R&D highlights
ATS and ERA data highlights improvement in patient outcomes across R&I and CVRM
Clear rationale for targeting
IL-33 in severe viral lung infection
CEO Opening Remarks
Post-index COPD Exacerbations
2.50
2.00
1.50
EROS: relationship between timing of Breztri
initiation and exacerbation rate
1.00
Initiating <30 days resulted in 24% reduction
in the risk of future exacerbations vs delaying
treatment up to six months
2.30
0.50
0.00
Financial Results
Breztri
Real-world evidence
2.00
1.52
Any exacerbation
1.46
Oncology
1.93
2.14
ATS
Moderate
exacerbation
Prompt initiation¹
Delayed initiation
Very delayed initiation
0.060.080.16
Severe
exacerbation
Exacerbation risk increased by 5% every
month Breztri treatment was delayed
●
BioPharmaceuticals
●
Rare Disease
CEO Closing Remarks
Farxiga and Lokelma CERA
LEADING EUROPEAN NEPHROLOGY
Real-world evidence and guideline updates
REVEAL-CKD: 85-97% Stage 3 CKD
undiagnosed²
Delaying diagnosis of CKD by one year:
risk of deterioration by 40%
risk of kidney transplant/long-term
dialysis treatment by 63%
ZORA highlighted role of Lokelma for
patients with HK whilst on RAASI
CKD and HF guidelines³ recommend and
support use of K+ binders
Highlights importance of early diagnosis
and concomitant K+ use in RAASI therapy
1. Prompt initiation initiated therapy ≤30 days, Delayed initiation initiated therapy >30 - <180 days, Very delayed initiation initiated therapy 180 days. 2. REVEAL-CKD multinational study, data referenced includes Spain, Australia, Canada and Brazil.
3. Guidelines include: KDIGO (HTN in CKD and Diabetic Kidney), ESC (HF), AHA/ACC/HFSA (HF)
22 ATS = American Thoracic Society; ERA = European Renal Association; R&I = Respiratory & Immunology; CVRM = Cardiovascular, Renal & Metabolism; IL-33= interleukin-33; red= reduced form; SST2 = soluble serum stimulated-2; COPD = chronic
obstructive pulmonary disease; CKD = chronic kidney disease, HK = hyperkalaemia; RAASI = renin-angiotensin-aldosterone system inhibitor; HF = heart failure; K+ = potassium.View entire presentation